Genetic modifications of the adeno-associated virus type 2 capsid reduce the affinity and the neutralizing effects of human serum antibodies
Open Access
- 17 November 2003
- journal article
- research article
- Published by Springer Nature in Gene Therapy
- Vol. 10 (26) , 2139-2147
- https://doi.org/10.1038/sj.gt.3302123
Abstract
The high prevalence of human serum antibodies against adeno-associated virus type 2 (AAV) vectors represents a potential limitation for in vivo applications. Consequently, the development of AAV vectors able to escape antibody binding and neutralization is of importance. To identify capsid domains which contain major immunogenic epitopes, six AAV capsid mutants carrying peptide insertions in surface exposed loop regions (I-261, I-381, I-447, I-534, I-573, I-587) were analyzed. Two of these mutants, I-534 and I-573, showed an up to 70% reduced affinity for AAV antibodies as compared to wild-type AAV in the majority of serum samples. In addition, AAV mutant I-587 but not wild-type AAV efficiently transduced cells despite the presence of neutralizing antisera. Taken together, the results show that major neutralizing effects of human AAV antisera might be overcome by the use of AAV capsid mutants.Keywords
This publication has 52 references indexed in Scilit:
- In vitro selection of viral vectors with modified tropism: the adeno-associated virus displayMolecular Therapy, 2003
- Adeno-Associated Virus Capsids Displaying Immunoglobulin-Binding Domains Permit Antibody-Mediated Vector Retargeting to Specific Cell Surface ReceptorsJournal of Virology, 2002
- Real-Time Single-Molecule Imaging of the Infection Pathway of an Adeno-Associated VirusScience, 2001
- Insertional Mutagenesis of the Adeno-Associated Virus Type 2 (AAV2) Capsid Gene and Generation of AAV2 Vectors Targeted to Alternative Cell-Surface ReceptorsHuman Gene Therapy, 2001
- Efficient and Selective AAV2-Mediated Gene Transfer Directed to Human Vascular Endothelial CellsMolecular Therapy, 2001
- Incorporation of Tumor-Targeting Peptides into Recombinant Adeno-associated Virus CapsidsMolecular Therapy, 2001
- Intracellular Trafficking of Adeno-Associated Virus Vectors: Routing to the Late Endosomal Compartment and Proteasome DegradationJournal of Virology, 2001
- Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2Gene Therapy, 1999
- Recombinant adeno-associated virus purification using novel methods improves infectious titer and yieldGene Therapy, 1999
- Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brainNature Genetics, 1994